Strides Pharma gets USFDA nod for colchicine tablets
Strides said the product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc in the US market.
New Delhi: Drug firm Strides Pharma Science on Friday said its subsidiary has received approval from the US health regulator to sell colchicine tablets, used for the treatment and prevention of gout, in the American market. Singapore-based Strides Pharma Global Pte, a step down wholly-owned subsidiary of the company, has received approval from the United States Food & Drug Administration (USFDA) to market the product, Strides Pharma Science said in a statement.
Strides has a global manufacturing footprint with eight manufacturing facilities spread across four continents, including five US FDA approved facilities and two facilities for the rest of world markets .
The Company has a dedicated R&D facility in India with global filing capabilities and a strong footprint across 100 countries.
Read Also - Strides Pharma, Medicines Patent Pool ink pact to commercialize molnupiravir for global markets
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd